Shelton Capital Management’s GSK GSK Stock Holding History

Shelton Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,273	Closed	-$450K	–	764
2022 Q1	$450K	Hold	8,273	–	–	0.02%	385
2021 Q4	$456K	Hold	8,273	–	–	0.02%	397
2021 Q3	$395K	Hold	8,273	–	–	0.02%	432
2021 Q2	$412K	Hold	8,273	–	–	0.02%	434
2021 Q1	$369K	Hold	8,273	–	–	0.01%	465
2020 Q4	$381K	Hold	8,273	–	–	0.02%	417
2020 Q3	$389K	Hold	8,273	–	–	0.02%	473
2020 Q2	$422K	Hold	8,273	–	–	0.02%	353
2020 Q1	$392K	Buy	8,273 +208	+3%	+$11.1K	0.03%	336
2019 Q4	$474K	Hold	8,065	–	–	0.03%	370
2019 Q3	$430K	Hold	8,065	–	–	0.03%	394
2019 Q2	$403K	Buy	8,065 +7,728	+2,293%	+$388K	0.02%	416
2019 Q1	$10.1K	Sell	337 -7,728	-96%	-$386K	0.04%	401
2018 Q4	$385K	Sell	8,065 -3,360	-29%	-$165K	0.03%	379
2018 Q3	$574K	Sell	11,425 -4,260	-27%	-$216K	0.03%	326
2018 Q2	$790K	Hold	15,685	–	–	0.05%	260
2018 Q1	$766K	Sell	15,685 -2,180	-12%	-$102K	0.05%	270
2017 Q4	$792K	Sell	17,865 -4,800	-21%	-$222K	0.05%	275
2017 Q3	$1.15M	Buy	22,665 +9,600	+73%	+$487K	0.08%	211
2017 Q2	$704K	Hold	13,065	–	–	0.05%	284
2017 Q1	$689K	Hold	13,065	–	–	0.05%	290
2016 Q4	$629K	Hold	13,065	–	–	0.05%	310
2016 Q3	$704K	Sell	13,065 -9	-0.1%	-$493	0.06%	275
2016 Q2	$708K	Buy	13,074 +9	+0.1%	+$474	0.06%	274
2016 Q1	$662K	Hold	13,065	–	–	0.06%	290
2015 Q4	$659K	Hold	13,065	–	–	0.06%	267
2015 Q3	$628K	Hold	13,065	–	–	0.07%	269
2015 Q2	$680K	Hold	13,065	–	–	0.07%	268
2015 Q1	$754K	Hold	13,065	–	–	0.08%	245
2014 Q4	$698K	Buy	13,065 +6,625	+103%	+$371K	0.08%	249
2014 Q3	$370K	Buy	+6,440	New	+$395K	0.05%	463

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Shelton Capital Management's GSK Position: Q2 2022 in Review

Shelton Capital Management sold out of GSK (GSK) in Q2 2022, closing a stake of 8,273 shares — an estimated $450K sold.

Shelton Capital Management first reported a position in GSK in Q3 2014 and held it in 31 quarters. The position peaked at $1.15M in Q3 2017. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

Shelton Capital Management reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
Shelton Capital Management sold 8,273 GSK shares in Q2 2022, an estimated $450K.
Shelton Capital Management first reported a position in GSK in Q3 2014 and held it in 31 quarters.
Shelton Capital Management's GSK position peaked at $1.15M in Q3 2017.
900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Shelton Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.